Apathy

Last updated

Mental state in terms of challenge level and skill level, according to Csikszentmihalyi's flow model. (Click on a fragment of the image to go to the appropriate article) Challenge vs skill.svg
Mental state in terms of challenge level and skill level, according to Csikszentmihalyi's flow model. (Click on a fragment of the image to go to the appropriate article)

Apathy, also referred to as indifference, is a lack of feeling, emotion, interest, or concern about something. It is a state of indifference, or the suppression of emotions such as concern, excitement, motivation, or passion. An apathetic individual has an absence of interest in or concern about emotional, social, spiritual, philosophical, virtual, or physical life and the world. Apathy can also be defined as a person's lack of goal orientation. [2] Apathy falls in the less extreme spectrum of diminished motivation, with abulia in the middle and akinetic mutism being more extreme than both apathy and abulia. [3]

Contents

The apathetic may lack a sense of purpose, worth, or meaning in their life. People with severe apathy tend to have a lower quality of life and are at a higher risk for mortality and early institutionalization. [2] They may also exhibit insensibility or sluggishness. [4] In positive psychology, apathy is described as a result of the individuals' feeling they do not possess the level of skill required to confront a challenge (i.e. "flow"). It may also be a result of perceiving no challenge at all (e.g., the challenge is irrelevant to them, or conversely, they have learned helplessness). Apathy is usually felt only in the short term, but sometimes it becomes a long-term or even lifelong state, often leading to deeper social and psychological issues. [5] [4]

Apathy should be distinguished from reduced affect display, which refers to reduced emotional expression but not necessarily reduced emotion.

Pathological apathy, characterized by extreme forms of apathy, is now known to occur in many different brain disorders, [6] including neurodegenerative conditions often associated with dementia such as Alzheimer's disease, [7] Parkinson's disease, [8] and psychiatric disorders such as schizophrenia. [9] Although many patients with pathological apathy also have depression, several studies have shown that the two syndromes are dissociable: apathy can occur independent of depression and vice versa. [6]

Etymology

Although the word apathy was first used in 1594 [10] and is derived from the Greek ἀπάθεια ( apatheia ), from ἀπάθης (apathēs, "without feeling" from a- ("without, not") and pathos ("emotion")), [11] it is important not to confuse the two terms. Also meaning "absence of passion," "apathy" or "insensibility" in Greek, the term apatheia was used by the Stoics to signify a (desirable) state of indifference toward events and things that lie outside one's control (that is, according to their philosophy, all things exterior, one being only responsible for one's own representations and judgments). [12] In contrast to apathy, apatheia is considered a virtue, especially in Orthodox monasticism. [13] In the Philokalia the word dispassion is used for apatheia, so as not to confuse it with apathy. [14]

History and other views

Christians have historically condemned apathy as a deficiency of love and devotion to God and his works. [15] This interpretation of apathy is also referred to as Sloth and is listed among the Seven Deadly Sins. Clemens Alexandrinus used the term to draw to gnostic Christianity philosophers who aspired after virtue. [16]

The modern concept of apathy became more well known after World War I, when it was one of the various forms of "shell shock", now better known as post-traumatic stress disorder (PTSD). [17] Soldiers who lived in the trenches amidst the bombing and machine gun fire, and who saw the battlefields strewn with dead and maimed comrades, developed a sense of disconnected numbness and indifference to normal social interaction when they returned from combat.

In 1950, US novelist John Dos Passos wrote: "Apathy is one of the characteristic responses of any living organism when it is subjected to stimuli too intense or too complicated to cope with. The cure for apathy is comprehension." [18]

Social origin

There may be other factors contributing to a person's apathy.

Apathy has been socially viewed as worse than things such as hate or anger. Not caring whatsoever, in the eyes of some, is even worse than having distaste for something. Author Leo Buscaglia is quoted as saying "I have a very strong feeling that the opposite of love is not hate-it's apathy. It's not giving a damn." [19] Helen Keller stated that apathy is the "worst of them all" when it comes to the various evils in the world. [20] French social commentator and political thinker Charles de Montesquieu stated that "the tyranny of a prince in an oligarchy is not so dangerous to the public welfare as the apathy of a citizen in the democracy." [21] As can be seen by these quotes and various others, the social implications of apathy are great. Many people believe that not caring at all can be worse for society than individuals who are overpowering or hateful.

In the school system

Apathy in students, especially those in high school, is a growing problem. It causes teachers to lower standards in order to try to engage their students. [22] Apathy in schools is most easily recognized by students being unmotivated or, quite commonly, being motivated by outside factors. For example, when asked about their motivation for doing well in school, fifty percent of students cited outside sources such as "college acceptance" or "good grades". On the contrary, only fourteen percent cited "gaining an understanding of content knowledge or learning subject material" as their motivation to do well in school. As a result of these outside sources, and not a genuine desire for knowledge, students often do the minimum amount of work necessary to get by in their classes. [22] This then leads to average grades and test grades but no real grasping of knowledge. [22] Many students cited that "assignments/content was irrelevant or meaningless" and that this was the cause of their apathetic attitudes toward their schooling, leading to teacher and parent frustration. [23] Other causes of apathy in students include situations within their home life, media influences, peer influences, school struggles and failures. Some of the signs of apathetic students include declining grades, skipping classes, routine illness, and behavioral changes both in school and at home. In order to combat this, teachers have to be aware that students have different motivation profiles; [24] i.e. they are motivated by different factors or stimuli.

Bystander

Also known as the bystander effect, bystander apathy occurs when, during an emergency, those standing by do nothing to help but instead stand by and watch. Sometimes this can be caused by one bystander observing other bystanders and imitating their behavior. If other people are not acting in a way that makes the situation seem like an emergency that needs attention, often other bystanders will act in the same way. [25] The diffusion to responsibility can also be to blame for bystander apathy. The more people that are around in emergency situations, the more likely individuals are to think that someone else will help so they do not need to. This theory was popularized by social psychologists in response to the 1964 Kitty Genovese murder. The murder took place in New York and the victim, Genovese, was stabbed to death as bystanders reportedly stood by and did nothing to stop the situation or even call the police. [25] Latané and Darley are the two psychologists who did research on this theory. They performed different experiments that placed people into situations where they had the opportunity to intervene or do nothing. The individuals in the experiment were either by themselves, with a stranger(s), with a friend, or with a confederate. The experiments ultimately led them to the conclusion that there are many social and situational factors that are behind whether a person will react in an emergency situation or simply remain apathetic to what is occurring.[ citation needed ]

Measurement

Several different questionnaires and clinical interview instruments have been used to measure pathological apathy or, more recently, apathy in healthy people.

Apathy Evaluation Scale

Developed by Robert Marin in 1991, the Apathy Evaluation Scale (AES) was the first method developed to measure apathy in clinical populations. Centered around evaluation, the scale can either be self-informed or other-informed. The three versions of the test include self, informant such as a family member, and clinician. The scale is based around questionnaires that ask about topics including interest, motivation, socialization, and how the individual spends their time. The individual or informant answers on a scale of "not at all", "slightly", "somewhat" or "a lot". Each item on the evaluation is created with positive or negative syntax and deals with cognition, behavior, and emotion. Each item is then scored and, based on the score, the individual's level of apathy can be evaluated. [26] [27]

Apathy Motivation Index

The Apathy Motivation Index (AMI) was developed to measure different dimensions of apathy in healthy people. Factor analysis identified three distinct axes of apathy: behavioural, social and emotional. [28] The AMI has since been used to examine apathy in patients with Parkinson's disease who, overall, showed evidence of behavioural and social apathy, but not emotional apathy. [29] Patients with Alzheimer's disease, Parkinson's disease, subjective cognitive impairment and limbic encephalitis have also been assessed using the AMI, and their self-reports of apathy were compared with those of caregivers using the AMI caregiver scale. [30]

Dimensional Apathy Scale

The Dimensional Apathy Scale (DAS) is a multidimensional apathy instrument for measuring subtypes of apathy in different clinical populations and healthy adults. It was developed using factor analysis, quantifying Executive apathy (lack of motivation for planning, organising and attention), Emotional apathy (emotional indifference, neutrality, flatness or blunting) and Initiation apathy (lack of motivation for self-generation of thought/action). There is a self-rated version of the DAS [31] and an informant/carer-rated version of the DAS. [32] Further a clinical brief DAS has also been developed. [33] It has been validated for use in stroke, Huntington's disease, motor neurone disease, Multiple Sclerosis, dementia, Parkinson's disease and schizophrenia, showing to differentiate profiles of apathy subtypes between these conditions. [34] [35] [36] [37] [38]

Medical aspects

Depression

Mental health journalist and author John McManamy argues that although psychiatrists do not explicitly deal with the condition of apathy, it is a psychological problem for some depressed people, in which they get a sense that "nothing matters", the "lack of will to go on and the inability to care about the consequences". [39] [ self-published source? ] He describes depressed people who "...cannot seem to make [themselves] do anything", who "can't complete anything", and who do not "feel any excitement about seeing loved ones". [39] He acknowledges that the Diagnostic and Statistical Manual of Mental Disorders does not discuss apathy.

In a Journal of Neuropsychiatry and Clinical Neurosciences article from 1991, Robert Marin, MD, claimed that pathological apathy occurs due to brain damage or neuropsychiatric illnesses such as Alzheimer's, Parkinson's, Huntington's disease, or stroke. Marin argues that apathy is a syndrome associated with many different brain disorders. [39] This has now been shown to be the case across a range of neurological and psychiatric conditions. [6]

A review article by Robert van Reekum, MD, et al. from the University of Toronto in the Journal of Neuropsychiatry (2005) claimed that an obvious relationship between depression and apathy exists in some populations. [40] However, although many patients with depression also have apathy, several studies have shown that apathy can occur independently of depression, and vice versa. [6]

Apathy can be associated with depression, a manifestation of negative disorders in schizophrenia, or a symptom of various somatic and neurological disorders. [41] [6] Sometimes apathy and depression are viewed as the same thing, but actually take different forms depending on someone's mental condition. [42]

Alzheimer's disease

Depending upon how it has been measured, apathy affects 19–88% percent of individuals with Alzheimer's disease (mean prevalence of 49% across different studies). [7] It is a neuropsychiatric symptom associated with functional impairment. Brain imaging studies have demonstrated changes in the anterior cingulate cortex, orbitofrontal cortex, dorsolateral prefrontal cortex and ventral striatum in Alzheimer's patients with apathy. [43] Cholinesterase inhibitors, used as the first line of treatment for the cognitive symptoms associated with dementia, have also shown some modest benefit for behavior disturbances such as apathy. [44] The effects of donepezil, galantamine and rivastigmine have all been assessed but, overall, the findings have been inconsistent, and it is estimated that apathy in ~60% of Alzheimer's patients does not respond to treatment with these drugs. [7] Methylphenidate, a dopamine and noradrenaline reuptake blocker, has received increasing interest for the treatment of apathy. Management of apathetic symptoms using methylphenidate has shown promise in randomized placebo controlled trials of Alzheimer's patients. [45] [46] [47] A phase III multi-centered randomized placebo-controlled trial of methylphenidate for the treatment of apathy has reported positive effects. [48]

Parkinson's disease

Overall, ~40% of Parkinson's disease patients suffer from apathy, with prevalence rates varying from 16 to 62%, depending on the study. [8]  Apathy is increasingly recognized to be an important non-motor symptom in Parkinson's disease. [49] It has a significant negative impact on quality of life. [50] In some patients, apathy can be improved by dopaminergic medication. [51] There is also some evidence for a positive effect of cholinesterase inhibitors such as Rivastigmine on apathy. [52] Diminished sensitivity to reward may be a key component of the syndrome in Parkinson's disease. [53] [54]

Frontotemporal dementia

Pathological apathy is considered to be one of the diagnostic features of behavioural variant frontotemporal dementia, [55] occurring in the majority of people with this condition. [56] Both hypersensitivity to effort as well as blunting of sensitivity to reward may be components of behavioural apathy in frontotemporal dementia. [57]

Anxiety

While apathy and anxiety may appear to be separate, and different, states of being, there are many ways that severe anxiety can cause apathy. First, the emotional fatigue that so often accompanies severe anxiety leads to one's emotions being worn out, thus leading to apathy. Second, the low serotonin levels associated with anxiety often lead to less passion and interest in the activities in one's life, which can be seen as apathy. Third, negative thinking and distractions associated with anxiety can ultimately lead to a decrease in one's overall happiness which can then lead to an apathetic outlook about one's life. Finally, the difficulty enjoying activities that individuals with anxiety often face can lead to them doing these activities much less often and can give them a sense of apathy about their lives. Even behavioral apathy may be found in individuals with anxiety in the form of them not wanting to make efforts to treat their anxiety. [58]

Other

Often, apathy is felt after witnessing horrific acts, such as the killing or maiming of people during a war, e.g. posttraumatic stress disorder. It is also known to be a distinct psychiatric syndrome [59] that is associated with many conditions, more prominently recognized in the elderly, some of which are: CADASIL syndrome, depression, Alzheimer's disease, Chagas disease, Creutzfeldt–Jakob disease, dementia (and dementias such as Alzheimer's disease, vascular dementia, and frontotemporal dementia), Korsakoff's syndrome, excessive vitamin D, hypothyroidism, hyperthyroidism, general fatigue, Huntington's disease, Pick's disease, progressive supranuclear palsy (PSP), brain damage, schizophrenia, schizoid personality disorder, bipolar disorder, [60] autism spectrum disorders, ADHD, and others. Some medications and the heavy use of drugs such as opiates may bring apathy as a side effect. [61]

See also

Notes

  1. ↑ Csikszentmihalyi M (1997). Finding Flow: The Psychology of Engagement with Everyday Life (1st ed.). New York: Basic Books. p. 31. ISBN   978-0-465-02411-7.
  2. 1 2 Fahed M, Steffens DC (May 2021). "Apathy: Neurobiology, Assessment and Treatment". Clinical Psychopharmacology and Neuroscience. 19 (2): 181–189. doi:10.9758/cpn.2021.19.2.181. PMC   8077060 . PMID   33888648.
  3. ↑ Marin, R. S., & Wilkosz, P. A. (2005). Disorders of diminished motivation Archived 2012-11-22 at the Wayback Machine . Journal of Head Trauma Rehabilitation, 20(4), 377-388.
  4. 1 2 "Apathy". Cleveland Clinic. Retrieved 30 December 2023.
  5. ↑ Pishghadam, Reza; Faribi, Maryam; Kolahi Ahari, Mahtab; Shadloo, Farzaneh; Gholami, Mohammad Javad; Shayesteh, Shaghayegh (29 August 2022). "Intelligence, emotional intelligence, and emo-sensory intelligence: Which one is a better predictor of university students' academic success?". Frontiers in Psychology. 13. doi: 10.3389/fpsyg.2022.995988 . ISSN   1664-1078. PMC   9465416 . PMID   36106040.
  6. 1 2 3 4 5 Husain M, Roiser JP (August 2018). "Neuroscience of apathy and anhedonia: a transdiagnostic approach" (PDF). Nature Reviews. Neuroscience. 19 (8): 470–484. doi:10.1038/s41583-018-0029-9. PMID   29946157. S2CID   49428707.
  7. 1 2 3 Nobis L, Husain M (August 2018). "Apathy in Alzheimer's disease". Current Opinion in Behavioral Sciences. 22: 7–13. doi:10.1016/j.cobeha.2017.12.007. PMC   6095925 . PMID   30123816.
  8. 1 2 den Brok, Melina G. H. E.; van Dalen, Jan Willem; van Gool, Willem A.; Moll van Charante, Eric P.; de Bie, Rob M. A.; Richard, Edo (May 2015). "Apathy in Parkinson's disease: A systematic review and meta-analysis". Movement Disorders. 30 (6): 759–769. doi:10.1002/mds.26208. ISSN   1531-8257. PMID   25787145. S2CID   35664376.
  9. ↑ Bortolon C, Macgregor A, Capdevielle D, Raffard S (September 2018). "Apathy in schizophrenia: A review of neuropsychological and neuroanatomical studies". Neuropsychologia. 118 (Pt B): 22–33. doi:10.1016/j.neuropsychologia.2017.09.033. PMID   28966139. S2CID   13411386.
  10. ↑ "Apathy - Definition and More from the Free Merriam-Webster Dictionary". Merriam-webster.com. Retrieved 25 February 2014.
  11. ↑ "Henry George Liddell, Robert Scott, A Greek-English Lexicon, ἀπάθ-εια". Perseus.tufts.edu. Retrieved 25 February 2014.
  12. ↑ Fleming W (2006) [1857]. The vocabulary of philosophy, mental, moral, and metaphysical. Kessinger Publishing. p. 34. ISBN   978-1-4286-3324-7. and in hardcover (2007; ISBN   978-0-548-12371-3).
  13. ↑ Linjamaa P (2019). "Emotions, Demons, and Moral Ability". The Ethics of The Tripartite Tractate (NHC I, 5). A Study of Determinism and Early Christian Philosophy of Ethics. Brill. pp. 71–111. ISBN   978-90-04-40775-6. JSTOR   10.1163/j.ctv1sr6hq6.7.
  14. ↑ Carey J (2018). "Dispassion as an Ethical Ideal". Ergo, an Open Access Journal of Philosophy. 5 (20201214). doi: 10.3998/ergo.12405314.0005.024 . hdl:2027/spo.12405314.0005.024. ISSN   2330-4014. S2CID   59323805.
  15. ↑ "Greek Lexicon :: G543 (KJV)". V3.blueletterbible.org. Archived from the original on 2 October 2017. Retrieved 25 February 2014.
  16. ↑ Maier, H.O. (1994). "Clement of Alexandria and the Care of the Self". Journal of the American Academy of Religion. 62 (3): 720–721.
  17. ↑ Webb TE (July 2006). "'Dottyville'--Craiglockhart War Hospital and shell-shock treatment in the First World War". Journal of the Royal Society of Medicine. 99 (7): 342–346. doi:10.1177/014107680609900716. PMC   1484566 . PMID   16816263.
  18. ↑ Passos, John (1950). The Prospect Before Us. Houghton Mifflin. ISBN   978-1199716941.
  19. ↑ Buscaglia, Leo (1972). Love: A Warm and Wonderful Book About the Largest Experience in Life. Fawcett Books. ISBN   9780449234525.
  20. ↑ Keller H (1994) [1927]. "Chapter 6". Light in My Darkness . West Chester, Pa.: Chrysalis Books. ISBN   978-0-87785-146-2. But if we listen to the best men and women everywhere ... they will say that science may have found a cure for most evils; but it has found no remedy for the worst of them all—the apathy of human beings.
  21. ↑ ""The tyranny of a prince in an oligarchy is not so dangerous to the public welfare as the apathy of a citizen in a democracy."--Montesquieu, Spirit of the laws, 1748. From the series Great Ideas. | Smithsonian American Art Museum". americanart.si.edu. Retrieved 15 March 2024.
  22. 1 2 3 Bishop JH (January 1989). "Perspective: Why the Apathy in American High Schools?". Educational Researcher. 18 (1): 6–42. doi:10.3102/0013189X018001006. ISSN   0013-189X. S2CID   145803015.
  23. ↑ Sanders J, Ticktin R. "Finding the Root Cause of Student Apathy". Pan.intrasun.tcnj.edu. Archived from the original on 24 March 2013. Retrieved 25 February 2014. Apathy in High School Students: An Examination Into Causes and A Suggested Plan for Change
  24. ↑ Korpershoek H, Kuyper H, van der Werf G (1 March 2015). "Differences in students' school motivation: A latent class modelling approach". Social Psychology of Education. 18 (1): 137–163. doi:10.1007/s11218-014-9274-6. ISSN   1573-1928. S2CID   145228051.
  25. 1 2 Latané B, Darley JM (1969). "Bystanders "apathy"". American Scientist. 57 (2): 244–68. PMID   5797312. Archived from the original on 4 November 2013.
  26. ↑ Marin, Robert S.; Biedrzycki, Ruth C.; Firinciogullari, Sekip (1 August 1991). "Reliability and validity of the apathy evaluation scale". Psychiatry Research. 38 (2): 143–162. doi:10.1016/0165-1781(91)90040-V. ISSN   0165-1781.
  27. ↑ "Apathy Evaluation Scale (Self rated)" (PDF). Dementia-assessment.com.au. Archived from the original (PDF) on 26 January 2014. Retrieved 25 February 2014.
  28. ↑ Ang YS, Lockwood P, Apps MA, Muhammed K, Husain M (2017). "Distinct Subtypes of Apathy Revealed by the Apathy Motivation Index". PLOS ONE. 12 (1): e0169938. Bibcode:2017PLoSO..1269938A. doi: 10.1371/journal.pone.0169938 . PMC   5226790 . PMID   28076387.
  29. ↑ Ang YS, Lockwood PL, Kienast A, Plant O, Drew D, Slavkova E, et al. (October 2018). "Differential impact of behavioral, social, and emotional apathy on Parkinson's disease". Annals of Clinical and Translational Neurology. 5 (10): 1286–1291. doi:10.1002/acn3.626. PMC   6186939 . PMID   30349863.
  30. ↑ Klar, Verena S.; Ang, Yuen-Siang; Lockwood, Patricia; Attaallah, Bahaaeddin; Dickson, Shannon; Drew, Daniel; Kienast, Annika; Maio, Maria R.; Plant, Olivia; Slavkova, Elitsa; Toniolo, Sofia; Zambellas, Rhea; Irani, Sarosh R.; Husain, Masud (March 2022). "Assessment of apathy in neurological patients using the Apathy Motivation Index caregiver version". Journal of Neuropsychology. 16 (1): 236–258. doi:10.1111/jnp.12262. ISSN   1748-6653. PMC   9290131 . PMID   34532963.
  31. ↑ Radakovic R, Abrahams S (November 2014). "Developing a new apathy measurement scale: Dimensional Apathy Scale" (PDF). Psychiatry Research. 219 (3): 658–63. doi:10.1016/j.psychres.2014.06.010. hdl:20.500.11820/2c1a046b-3836-4890-8e38-f85436c76474. PMID   24972546. S2CID   16313833.
  32. ↑ Radakovic R, Stephenson L, Colville S, Swingler R, Chandran S, Abrahams S (June 2016). "Multidimensional apathy in ALS: validation of the Dimensional Apathy Scale" (PDF). Journal of Neurology, Neurosurgery, and Psychiatry. 87 (6): 663–9. doi:10.1136/jnnp-2015-310772. PMID   26203157. S2CID   15540782.
  33. ↑ Radakovic R, Stephenson L, Colville S, Swingler R, Chandran S, Abrahams S (June 2016). "Multidimensional apathy in ALS: validation of the Dimensional Apathy Scale" (PDF). Journal of Neurology, Neurosurgery, and Psychiatry. 87 (6): 663–9. doi:10.1080/13854046.2019.1621382. PMID   26203157. S2CID   173994534.
  34. ↑ Radakovic R, Abrahams S (2018). "Multidimensional apathy: evidence from neurodegenerative disease" (PDF). Current Opinion in Behavioral Sciences. 22: 42–49. doi:10.1016/j.cobeha.2017.12.022. S2CID   53173573.
  35. ↑ Atkins KJ, Andrews SC, Chong TT, Stout JC (April 2021). "Multidimensional Apathy: The Utility of the Dimensional Apathy Scale in Huntington's Disease". Movement Disorders Clinical Practice. 8 (3): 361–370. doi:10.1002/mdc3.13147. PMC   8015897 . PMID   33816664.
  36. ↑ Raimo S, Trojano L, Gaita M, Spitaleri D, Santangelo G (February 2020). "Assessing apathy in multiple sclerosis: Validation of the dimensional apathy scale and comparison with apathy evaluation scale". Multiple Sclerosis and Related Disorders. 38: 101870. doi:10.1016/j.msard.2019.101870. PMID   31830701. S2CID   209343166.
  37. ↑ Barek LM, Mercy G, Gautier C, Noquet M, Legros-Lafarge E, Fiegl L, et al. (November 2021). "The use of the French Dimensional Apathy Scale (f-DAS) to assess apathy in schizophrenia: Properties and profiles". Journal of Affective Disorders. 294: 181–188. doi: 10.1016/j.jad.2021.06.081 . PMID   34298224.
  38. ↑ Myhre P, Radakovic R, Ford C (March 2022). "Validation of the self-rated Dimensional Apathy Scale in community stroke survivors" (PDF). Journal of the Neurological Sciences. 434: 120103. doi:10.1016/j.jns.2021.120103. PMID   34999366. S2CID   245423518.
  39. 1 2 3 McManamy J. "Apathy Matters - Apathy and Depression: Psychiatry may not care about apathy, but that doesn't mean you shouldn't". Archived from the original on 20 August 2014.".
  40. ↑ van Reekum R, Stuss DT, Ostrander L (February 2005). "Apathy: why care?". The Journal of Neuropsychiatry and Clinical Neurosciences. 17 (1): 7–19. doi:10.1176/jnp.17.1.7. PMID   15746478.
  41. ↑ Andersson S, Krogstad JM, Finset A (March 1999). "Apathy and depressed mood in acquired brain damage: relationship to lesion localization and psychophysiological reactivity". Psychological Medicine. 29 (2): 447–456. doi:10.1017/s0033291798008046. PMID   10218936. S2CID   34996374.
  42. ↑ Levy ML, Cummings JL, Fairbanks LA, Masterman D, Miller BL, Craig AH, et al. (1 August 1998). "Apathy is not depression". The Journal of Neuropsychiatry and Clinical Neurosciences. 10 (3): 314–319. doi:10.1176/jnp.10.3.314. PMID   9706539.
  43. ↑ Le Heron C, Apps MA, Husain M (September 2018). "The anatomy of apathy: A neurocognitive framework for amotivated behaviour". Neuropsychologia. 118 (Pt B): 54–67. doi:10.1016/j.neuropsychologia.2017.07.003. PMC   6200857 . PMID   28689673.
  44. ↑ Malloy PF (2 November 2005). "Apathy and Its Treatment in Alzheimer's Disease and Other Dementias". Psychiatric Times.
  45. ↑ Herrmann N, Rothenburg LS, Black SE, Ryan M, Liu BA, Busto UE, Lanctôt KL (June 2008). "Methylphenidate for the treatment of apathy in Alzheimer disease: prediction of response using dextroamphetamine challenge". Journal of Clinical Psychopharmacology. 28 (3): 296–301. doi:10.1097/JCP.0b013e318172b479. PMID   18480686. S2CID   30971352.
  46. ↑ Rosenberg PB, Lanctôt KL, Drye LT, Herrmann N, Scherer RW, Bachman DL, Mintzer JE (August 2013). "Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo-controlled trial". The Journal of Clinical Psychiatry. 74 (8): 810–6. doi:10.4088/JCP.12m08099. PMC   3902018 . PMID   24021498.
  47. ↑ Lanctôt KL, Chau SA, Herrmann N, Drye LT, Rosenberg PB, Scherer RW, et al. (February 2014). "Effect of methylphenidate on attention in apathetic AD patients in a randomized, placebo-controlled trial". International Psychogeriatrics. 26 (2): 239–46. doi:10.1017/S1041610213001762. PMC   3927455 . PMID   24169147.
  48. ↑ Mintzer, Jacobo; Lanctôt, Krista L.; Scherer, Roberta W.; Rosenberg, Paul B.; Herrmann, Nathan; van Dyck, Christopher H.; Padala, Prasad R.; Brawman-Mintzer, Olga; Porsteinsson, Anton P.; Lerner, Alan J.; Craft, Suzanne; Levey, Allan I.; Burke, William; Perin, Jamie; Shade, David (November 2021). "Effect of Methylphenidate on Apathy in Patients With Alzheimer Disease: The ADMET 2 Randomized Clinical Trial". JAMA Neurology. 78 (11): 1324–1332. doi:10.1001/jamaneurol.2021.3356. ISSN   2168-6157. PMC   8477302 . PMID   34570180.
  49. ↑ Pagonabarraga, Javier; Kulisevsky, Jaime; Strafella, Antonio P.; Krack, Paul (May 2015). "Apathy in Parkinson's disease: clinical features, neural substrates, diagnosis, and treatment". The Lancet. Neurology. 14 (5): 518–531. doi:10.1016/S1474-4422(15)00019-8. hdl: 10609/92806 . ISSN   1474-4465. PMID   25895932. S2CID   43614772.
  50. ↑ Benito-León, Julián; Cubo, Esther; Coronell, Carlos; ANIMO Study Group (February 2012). "Impact of apathy on health-related quality of life in recently diagnosed Parkinson's disease: the ANIMO study". Movement Disorders. 27 (2): 211–218. doi:10.1002/mds.23872. hdl: 10553/48392 . ISSN   1531-8257. PMID   21780179. S2CID   35925068.
  51. ↑ Thobois, Stéphane; Lhommée, Eugénie; Klinger, Hélène; Ardouin, Claire; Schmitt, Emmanuelle; Bichon, Amélie; Kistner, Andrea; Castrioto, Anna; Xie, Jing; Fraix, Valerie; Pelissier, Pierre; Chabardes, Stephan; Mertens, Patrick; Quesada, Jean-Louis; Bosson, Jean-Luc (May 2013). "Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil". Brain: A Journal of Neurology. 136 (Pt 5): 1568–1577. doi: 10.1093/brain/awt067 . ISSN   1460-2156. PMID   23543483.
  52. ↑ Devos, David; Moreau, Caroline; Maltête, David; Lefaucheur, Romain; Kreisler, Alexandre; Eusebio, Alexandre; Defer, Gilles; Ouk, Thavarak; Azulay, Jean-Philippe; Krystkowiak, Pierre; Witjas, Tatiana; Delliaux, Marie; Destée, Alain; Duhamel, Alain; Bordet, Régis (June 2014). "Rivastigmine in apathetic but dementia and depression-free patients with Parkinson's disease: a double-blind, placebo-controlled, randomised clinical trial". Journal of Neurology, Neurosurgery, and Psychiatry. 85 (6): 668–674. doi:10.1136/jnnp-2013-306439. ISSN   1468-330X. PMID   24218528. S2CID   7052710.
  53. ↑ Muhammed, Kinan; Manohar, Sanjay; Ben Yehuda, Michael; Chong, Trevor T.-J.; Tofaris, George; Lennox, Graham; Bogdanovic, Marko; Hu, Michele; Husain, Masud (October 2016). "Reward sensitivity deficits modulated by dopamine are associated with apathy in Parkinson's disease". Brain: A Journal of Neurology. 139 (Pt 10): 2706–2721. doi:10.1093/brain/aww188. ISSN   1460-2156. PMC   5035817 . PMID   27452600.
  54. ↑ Le Heron, Campbell; Plant, Olivia; Manohar, Sanjay; Ang, Yuen-Siang; Jackson, Matthew; Lennox, Graham; Hu, Michele T.; Husain, Masud (May 2018). "Distinct effects of apathy and dopamine on effort-based decision-making in Parkinson's disease". Brain: A Journal of Neurology. 141 (5): 1455–1469. doi:10.1093/brain/awy110. ISSN   1460-2156. PMC   5917786 . PMID   29672668.
  55. ↑ Rascovsky, Katya; Hodges, John R.; Knopman, David; Mendez, Mario F.; Kramer, Joel H.; Neuhaus, John; van Swieten, John C.; Seelaar, Harro; Dopper, Elise G. P.; Onyike, Chiadi U.; Hillis, Argye E.; Josephs, Keith A.; Boeve, Bradley F.; Kertesz, Andrew; Seeley, William W.; Rankin, Katherine P.; Johnson, Julene K.; Gorno-Tempini, Maria-Luisa; Rosen, Howard; Prioleau-Latham, Caroline E.; Lee, Albert; Kipps, Christopher M.; Lillo, Patricia; Piguet, Olivier; Rohrer, Jonathan D.; Rossor, Martin N.; Warren, Jason D.; Fox, Nick C.; Galasko, Douglas; Salmon, David P.; Black, Sandra E.; Mesulam, Marsel; Weintraub, Sandra; Dickerson, Brad C.; Diehl-Schmid, Janine; Pasquier, Florence; Deramecourt, Vincent; Lebert, Florence; Pijnenburg, Yolande; Chow, Tiffany W.; Manes, Facundo; Grafman, Jordan; Cappa, Stefano F.; Freedman, Morris; Grossman, Murray; Miller, Bruce L. (September 2011). "Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia". Brain. 134 (9): 2456–2477. doi: 10.1093/brain/awr179 . PMC   3170532 . PMID   21810890.
  56. ↑ Johnson, Emma; Kumfor, Fiona (August 2018). "Overcoming apathy in frontotemporal dementia: challenges and future directions". Current Opinion in Behavioral Sciences. 22: 82–89. doi:10.1016/j.cobeha.2018.01.022.
  57. ↑ Husain, Masud (13 February 2023). "Mechanisms underlying apathy in frontotemporal dementia". Brain. 146 (2): 416–417. doi: 10.1093/brain/awac494 . PMID   36567496.
  58. ↑ Abraham M (10 October 2020). "Apathy: Anxiety's Unusual Symptom". Calm Clinic. Retrieved 25 February 2014.
  59. ↑ Sederer L (26 July 2012). "The Enemy Is Apathy". Psychiatric Times.
  60. ↑ Ishii, Shinya; Weintraub, Nancy; Mervis, James R. (1 July 2009). "Apathy: A Common Psychiatric Syndrome in the Elderly". Journal of the American Medical Directors Association. 10 (6): 381–393. doi:10.1016/j.jamda.2009.03.007. ISSN   1525-8610. PMID   19560715.
  61. ↑ Baldini A, Von Korff M, Lin EH (14 June 2012). "A Review of Potential Adverse Effects of Long-Term Opioid Therapy: A Practitioner's Guide". The Primary Care Companion for CNS Disorders. 14 (3). doi:10.4088/PCC.11m01326. PMC   3466038 . PMID   23106029.

Related Research Articles

<span class="mw-page-title-main">Dementia</span> Long-term brain disorders causing impaired memory, thinking and behavior

Dementia is a syndrome associated with many neurodegenerative diseases, characterized by a general decline in cognitive abilities that affects a person's ability to perform everyday activities. This typically involves problems with memory, thinking, behavior, and motor control. Aside from memory impairment and a disruption in thought patterns, the most common symptoms of dementia include emotional problems, difficulties with language, and decreased motivation. The symptoms may be described as occurring in a continuum over several stages. Dementia ultimately has a significant effect on the individual, their caregivers, and their social relationships in general. A diagnosis of dementia requires the observation of a change from a person's usual mental functioning and a greater cognitive decline than might be caused by the normal aging process.

<span class="mw-page-title-main">Parkinsonism</span> Syndrome characterized by tremor, slowed movements, rigidity, and imbalance

Parkinsonism is a clinical syndrome characterized by tremor, bradykinesia, rigidity, and postural instability. Both hypokinetic as well as hyperkinetic features are displayed by Parkinsonism. These are the four motor symptoms found in Parkinson's disease (PD) – after which it is named – dementia with Lewy bodies (DLB), Parkinson's disease dementia (PDD), and many other conditions. This set of symptoms occurs in a wide range of conditions and may have many causes, including neurodegenerative conditions, drugs, toxins, metabolic diseases, and neurological conditions other than PD.

<span class="mw-page-title-main">Dementia with Lewy bodies</span> Type of progressive dementia

Dementia with Lewy bodies (DLB) is a type of dementia characterized by changes in sleep, behavior, cognition, movement, and regulation of automatic bodily functions. Memory loss is not always an early symptom. The disease worsens over time and is usually diagnosed when cognitive impairment interferes with normal daily functioning. Together with Parkinson's disease dementia, DLB is one of the two Lewy body dementias. It is a common form of dementia, but the prevalence is not known accurately and many diagnoses are missed. The disease was first described on autopsy by Kenji Kosaka in 1976, and he named the condition several years later.

<span class="mw-page-title-main">Caudate nucleus</span> Structure of the striatum in the basal ganglia of the brain

The caudate nucleus is one of the structures that make up the corpus striatum, which is part of the basal ganglia in the human brain. Although the caudate nucleus has long been associated with motor processes because of its role in Parkinson's disease, it also plays important roles in nonmotor functions, such as procedural learning, associative learning, and inhibitory control of action. The caudate is also one of the brain structures that compose the reward system, and it functions as part of the cortico-basal ganglia-thalamo-cortical loop.

<span class="mw-page-title-main">Frontotemporal dementia</span> Types of dementia involving the frontal or temporal lobes

Frontotemporal dementia (FTD), also called frontotemporal degeneration disease or frontotemporal neurocognitive disorder, encompasses several types of dementia involving the progressive degeneration of the brain's frontal and temporal lobes. Men and women appear to be equally affected. FTD generally presents as a behavioral or language disorder with gradual onset. Signs and symptoms tend to appear in late adulthood, typically between the ages of 45 and 65, although it can affect people younger or older than this. Currently, no cure or approved symptomatic treatment for FTD exists, although some off-label drugs and behavioral methods are prescribed.

In neurology, abulia, or aboulia, refers to a lack of will or initiative and can be seen as a disorder of diminished motivation. Abulia falls in the middle of the spectrum of diminished motivation, with apathy being less extreme and akinetic mutism being more extreme than abulia. The condition was originally considered to be a disorder of the will, and aboulic individuals are unable to act or make decisions independently; and their condition may range in severity from subtle to overwhelming. In the case of akinetic mutism, many patients describe that as soon as they "will" or attempt a movement, a "counter-will" or "resistance" rises up to meet them.

<span class="mw-page-title-main">Memantine</span> Medication used to treat Alzheimers disease

Memantine, sold under the brand name Namenda among others, is a medication used to slow the progression of moderate-to-severe Alzheimer's disease. It is taken by mouth.

<span class="mw-page-title-main">Progressive supranuclear palsy</span> Medical condition of the brain

Progressive supranuclear palsy (PSP) is a late-onset neurodegenerative disease involving the gradual deterioration and death of specific volumes of the brain. The condition leads to symptoms including loss of balance, slowing of movement, difficulty moving the eyes, and cognitive impairment. PSP may be mistaken for other types of neurodegeneration such as Parkinson's disease, frontotemporal dementia and Alzheimer's disease. The cause of the condition is uncertain, but involves the accumulation of tau protein within the brain. Medications such as levodopa and amantadine may be useful in some cases.

Cognitive disorders (CDs), also known as neurocognitive disorders (NCDs), are a category of mental health disorders that primarily affect cognitive abilities including learning, memory, perception, and problem-solving. Neurocognitive disorders include delirium, mild neurocognitive disorders, and major neurocognitive disorder. They are defined by deficits in cognitive ability that are acquired, typically represent decline, and may have an underlying brain pathology. The DSM-5 defines six key domains of cognitive function: executive function, learning and memory, perceptual-motor function, language, complex attention, and social cognition.

In neurology, semantic dementia (SD), also known as semantic variant primary progressive aphasia (svPPA), is a progressive neurodegenerative disorder characterized by loss of semantic memory in both the verbal and non-verbal domains. However, the most common presenting symptoms are in the verbal domain. Semantic dementia is a disorder of semantic memory that causes patients to lose the ability to match words or images to their meanings. However, it is fairly rare for patients with semantic dementia to develop category specific impairments, though there have been documented cases of it occurring. Typically, a more generalized semantic impairment results from dimmed semantic representations in the brain.

Progressive nonfluent aphasia (PNFA) is one of three clinical syndromes associated with frontotemporal lobar degeneration. PNFA has an insidious onset of language deficits over time as opposed to other stroke-based aphasias, which occur acutely following trauma to the brain. The specific degeneration of the frontal and temporal lobes in PNFA creates hallmark language deficits differentiating this disorder from other Alzheimer-type disorders by the initial absence of other cognitive and memory deficits. This disorder commonly has a primary effect on the left hemisphere, causing the symptomatic display of expressive language deficits and sometimes may disrupt receptive abilities in comprehending grammatically complex language.

<span class="mw-page-title-main">Primary progressive aphasia</span> Gradual impairment of language processing capabilities

In neuropathy, primary progressive aphasia (PPA) is a type of neurological syndrome in which language capabilities slowly and progressively become impaired. As with other types of aphasia, the symptoms that accompany PPA depend on what parts of the brain's left hemisphere are significantly damaged. However, unlike most other aphasias, PPA results from continuous deterioration in brain tissue, which leads to early symptoms being far less detrimental than later symptoms.

Memory disorders are the result of damage to neuroanatomical structures that hinders the storage, retention and recollection of memories. Memory disorders can be progressive, including Alzheimer's disease, or they can be immediate including disorders resulting from head injury.

<span class="mw-page-title-main">Frontal lobe disorder</span> Brain disorder

Frontal lobe disorder, also frontal lobe syndrome, is an impairment of the frontal lobe of the brain due to disease or frontal lobe injury. The frontal lobe plays a key role in executive functions such as motivation, planning, social behaviour, and speech production. Frontal lobe syndrome can be caused by a range of conditions including head trauma, tumours, neurodegenerative diseases, neurodevelopmental disorders, neurosurgery and cerebrovascular disease. Frontal lobe impairment can be detected by recognition of typical signs and symptoms, use of simple screening tests, and specialist neurological testing.

<span class="mw-page-title-main">Tauopathy</span> Medical condition

Tauopathies are a class of neurodegenerative diseases characterized by the aggregation of abnormal tau protein. Hyperphosphorylation of tau proteins causes them to dissociate from microtubules and form insoluble aggregates called neurofibrillary tangles. Various neuropathologic phenotypes have been described based on the anatomical regions and cell types involved as well as the unique tau isoforms making up these deposits. The designation 'primary tauopathy' is assigned to disorders where the predominant feature is the deposition of tau protein. Alternatively, diseases exhibiting tau pathologies attributed to different and varied underlying causes are termed 'secondary tauopathies'. Some neuropathologic phenotypes involving tau protein are Alzheimer's disease, frontotemporal dementia, progressive supranuclear palsy, and corticobasal degeneration.

The applause sign is a behavioural indicator, relevant to neurodegenerative conditions, characterised by a patient’s inability to execute the same number of hand claps as demonstrated by an examiner.

<span class="mw-page-title-main">Early onset dementia</span> Cognitive disorder

Early onset dementia or young onset dementia refers to dementia with symptom onset prior to age 65. This condition is a significant public health concern, as the number of individuals with early onset dementia is increasing worldwide.

Parkinson's disease dementia (PDD) is dementia that is associated with Parkinson's disease (PD). Together with dementia with Lewy bodies (DLB), it is one of the Lewy body dementias characterized by abnormal deposits of Lewy bodies in the brain.

The Cambridge Behavioural Inventory (CBI) and its revised version, Cambridge Behavioural Inventory-Revised (CBI-R), are informant-based questionnaires that evaluate the emergence of behavioural symptoms in neurodegenerative brain disorders, including Alzheimer's disease (AD), Huntington's disease (HD), Parkinson's disease (PD), and frontotemporal dementia (FTD).

<span class="mw-page-title-main">Masud Husain</span> British professor of neuroscience, editor of Brain

Masud Husain FMedSci is a clinical neurologist and neuroscientist working in the UK. He is Professor of Neurology & Cognitive Neuroscience at the Nuffield Department of Clinical Neurosciences and Departmental of Experimental Psychology, University of Oxford, a Professorial Fellow at New College, Oxford, and Editor-in-Chief of the journal Brain. He was born in East Pakistan.

References

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.